Rallybio Corp income statement

In fiscal 2025, Rallybio Corp reported revenue of $858,000, up 34.9% on the year before, operating income of −$33.1m (a -3853.6% margin) and net income of −$9.0m, or −$1.59 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Rallybio Corp: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	1	1	0
Research and development	42	20	8
General and administrative	20	14	17
Operating income	−60	−33	−24
Income before tax	−56	−9	27
Income tax	0	0	—
Net income	−58	−9	27
Diluted EPS	−$10.61	−$1.59	—
Diluted shares (average)	5m	6m	—
EBITDA	−60	−33	−24

US$ millions unless shown otherwise. Fiscal quarters.

Rallybio Corp: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	0	0	0	0	0	0	0	0
Research and development	7	6	6	4	4	3	1	1
General and administrative	4	4	4	3	3	6	5	3
Operating income	−12	−10	−10	−7	−6	−9	−6	−3
Income before tax	−11	−9	−9	16	−7	−8	45	−3
Income tax	—	—	0	0	0	—	1	0
Net income	−11	−9	−10	16	−6	−8	44	−3
Diluted EPS	−$9.53	−$1.69	−$1.76	$2.84	−$1.03	−$1.46	$7.53	−$0.48
EBITDA	−12	−10	−10	−7	−6	−9	−6	−3

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRDF vs RLYB CRVO vs RLYB MNOV vs RLYB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Rallybio Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rallybio Corp.